CBCT Assessment of Marginal Bone Changes With Ozone Therapy
ozone-ımplant
CBCT Assessment of Peri-Implant Marginal Bone Changes Following Adjunctive Local Ozone Therapy: A Randomized Split-Mouth Clinical Trial
1 other identifier
interventional
50
1 country
1
Brief Summary
This study examined whether adding local gaseous ozone to standard dental implant treatment could reduce early bone loss around implants. Fifty adults requiring matched implants on opposite sides of the same jaw participated. Within each participant, matched implant sites were randomly assigned to ozone treatment or standard treatment without ozone. Ozone was applied to the prepared implant socket during surgery and to the peri-implant surgical site after suturing and on postoperative days 1, 3, 5, and 7. Changes in marginal bone levels from baseline to 6 months were assessed using cone-beam computed tomography (CBCT).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Sep 2025
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 3, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 18, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
May 18, 2026
CompletedFirst Submitted
Initial submission to the registry
June 30, 2026
CompletedFirst Posted
Study publicly available on registry
July 7, 2026
CompletedSeptember 16, 2026
September 1, 2026
9 months
June 30, 2026
September 13, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Change in Marginal Bone Level Around Dental Implants
Using cone-beam computed tomography (CBCT), the vertical distance from the implant shoulder to the first bone-to-implant contact was measured in millimeters at the buccal, palatal/lingual, mesial, and distal surfaces at baseline and 6 months. For each surface, marginal bone level change was calculated as the 6-month distance minus the baseline distance; positive values indicated greater marginal bone loss. Combined buccolingual and mesiodistal measurements were calculated by averaging the corresponding surface measurements. Changes were compared between matched ozone-treated and control implant sites.
Baseline and 6 months after implant placement
Study Arms (2)
Gaseous Ozone Application
EXPERIMENTALWithin each participant, one or more matched implant sites were randomly allocated to adjunctive local gaseous ozone treatment. Ozone was applied to the surgically prepared implant socket before implant placement and to the peri-implant surgical site after suturing and on postoperative days 1, 3, 5, and 7. All sites also received standard surgical and postoperative care.
Conventional Implant Placement
ACTIVE COMPARATORWithin each participant, the corresponding contralateral matched implant site or sites were allocated to the control treatment. These sites received conventional implant placement and standard postoperative care without ozone application at any time point.
Interventions
Gaseous ozone was applied to the surgically prepared implant socket before implant placement. Following suturing, ozone was applied locally to the peri-implant surgical site and was repeated on postoperative days 1, 3, 5, and 7.
Implants were placed using the standard surgical protocol, followed by standard postoperative care, without intraoperative or postoperative ozone application.
Eligibility Criteria
You may qualify if:
- Adults aged 18 to 65 years.
- Systemically healthy individuals.
- Ability to comply with the study procedures and follow-up visits.
- Requirement for implant placement at matched contralateral posterior sites within the same jaw.
- Healed edentulous sites suitable for conventional implant placement.
- Adequate alveolar bone volume for placement of implants measuring 3.5-4.0 mm in diameter and 8-12 mm in length without the need for advanced bone augmentation, with at least 1.5 mm of surrounding bone.
- Initial soft-tissue thickness of at least 2 mm and keratinized mucosal width of at least 2 mm at the implant sites.
- Provision of written informed consent.
You may not qualify if:
- Systemic diseases or medical conditions contraindicating implant surgery.
- Pregnancy.
- Smoking.
- Active oral infection or advanced periodontal disease.
- Insufficient bone volume requiring advanced bone augmentation.
- Incomplete healing at the intended implant site following recent tooth extraction.
- Previous implant failure at the intended implant site.
- Any contraindication to ozone therapy.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Faculty of Dentistry, Adıyaman University
Adıyaman, Merkez, 02030, Turkey (Türkiye)
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
METİN ÇALIŞIR, PhD
Department of Periodontology, Faculty of Dentistry, Adıyaman University, Adıyaman, Turkey
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Masking Details
- The radiographic outcome assessor was blinded to treatment allocation. The operating surgeon was not blinded because of the nature of the intervention.
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Research Assistant in Periodontology
Study Record Dates
First Submitted
June 30, 2026
First Posted
July 7, 2026
Study Start
September 3, 2025
Primary Completion
May 18, 2026
Study Completion
May 18, 2026
Last Updated
September 16, 2026
Record last verified: 2026-09
Data Sharing
- IPD Sharing
- Will not share
Individual participant data will not be shared because the informed consent obtained from participants did not include external sharing of individual-level data. Aggregated study findings will be reported in the publication.